ARTICLE | Product Development
First glimpse of controlled remdesivir data cast doubt on its COVID-19 treatment potential
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
April 23, 2020 10:36 PM UTC
Updated on Apr 24, 2020 at 3:17 AM UTC
After weeks of encouraging anecdotal and uncontrolled data for Gilead’s COVID-19 therapy remdesivir, the first hint of results from a placebo-controlled trial suggest that if the antiviral does provide a benefit, it may be closely correlated to treatment timing.
Data accidentally published to the World Health Organization’s website showed that a Phase III trial of remdesivir in patients with severe COVID-19 had a negative outcome. ...
BCIQ Company Profiles